Across TCGA pan-cancer cohorts, CFC1 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated CFC1 data layer compared with 17 for mass-spec protein and 1 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher CFC1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CFC1 expression acts as an unfavorable survival marker.
UCEC are the cancer types where CFC1 Mutation most reproducibly stratifies survival.